- Home
- BYSI vs COEP Comparison
BYSI vs COEP Comparison
Compare BYSI & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- COEP
- Stock Information
- Founded
- BYSI 2010
- COEP 2017
- Country
- BYSI United States
- COEP United States
- Employees
- BYSI N/A
- COEP N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYSI Health Care
- COEP Health Care
- Exchange
- BYSI Nasdaq
- COEP Nasdaq
- Market Cap
- BYSI 73.4M
- COEP 62.4M
- IPO Year
- BYSI 2017
- COEP N/A
- Fundamental
- Price
- BYSI $1.72
- COEP $12.57
- Analyst Decision
- BYSI
- COEP
- Analyst Count
- BYSI 0
- COEP 0
- Target Price
- BYSI N/A
- COEP N/A
- AVG Volume (30 Days)
- BYSI 22.5K
- COEP 40.0K
- Earning Date
- BYSI 11-11-2025
- COEP 11-12-2025
- Dividend Yield
- BYSI N/A
- COEP N/A
- EPS Growth
- BYSI N/A
- COEP N/A
- EPS
- BYSI N/A
- COEP N/A
- Revenue
- BYSI N/A
- COEP $263,555.00
- Revenue This Year
- BYSI N/A
- COEP N/A
- Revenue Next Year
- BYSI N/A
- COEP N/A
- P/E Ratio
- BYSI N/A
- COEP N/A
- Revenue Growth
- BYSI N/A
- COEP N/A
- 52 Week Low
- BYSI $0.98
- COEP $2.31
- 52 Week High
- BYSI $3.44
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- BYSI 38.49
- COEP 51.06
- Support Level
- BYSI $1.77
- COEP $12.09
- Resistance Level
- BYSI $1.93
- COEP $13.25
- Average True Range (ATR)
- BYSI 0.12
- COEP 0.68
- MACD
- BYSI 0.00
- COEP -0.12
- Stochastic Oscillator
- BYSI 15.15
- COEP 45.47
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.